New BIOMARKER CONSORTIUM PROs

Aulus Cornelius Celsus wrote his famous book ‘De Medicina’ approximately 2000 years ago.  Living in the times of Caesar Augustus, little is known about his persona.  We are not even sure whether he was a practicing physician.  Many of his books were lost but Volume VIII was rediscovered in the Continue reading New BIOMARKER CONSORTIUM PROs

Treating Serious CRAB Infections

There are MDR pathogens, and there is carbapenem-resistant A. baumannii, aka CRAB. This surely must be one of the most formidable bacterial organisms. It has resistance mechanisms second to none.  When found in patients, it is very difficult to eradicate and extremely difficult to get rid off, once established in Continue reading Treating Serious CRAB Infections

IgAN Therapeutics – The Race is On

Is there a new trend in the journal world:  publication of interim analysis (IA) results? The NEJM recently published two articles back to back, both highlighting 9 month ‘interim’ data from Phase 3 pivotal trials in IgAN. The primary efficacy endpoint used in either study was UPCR at 9 months, Continue reading IgAN Therapeutics – The Race is On